UK collaboration for magnetotherapy technology:
This article was originally published in Clinica
Biotech firm Celltech has formed a UK collaboration to develop a magnetic-guided antibody therapy for treating cancer. The project will initially run for two years and will evaluate the use of Celltech's targeted antibody therapy in treating tumour cells with magnetically controlled nanoparticles. Researchers from the University of Durham will run the trials and will also be responsible for producing and coating the nanoparticles. Oxford Instruments Molecular Biotools will develop the external magnetic technology used to mediate the magnetically attached antibodies. Professor Mike Eaton, head of Celltech Antibody Chemistry, told Clinica that the antibody-targeted magnetotherapy could be available in clinics within the next five years. However, he declined to disclose any information about the nanoparticles used in the trials.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.